Chloroprocaine
A short-acting local anesthetic of the ester class that blocks sodium channels to reversibly inhibit nerve conduction, used primarily for epidural and spinal anesthesia in obstetric procedures. Its rapid hydrolysis by plasma cholinesterases results in a short duration of action and low systemic toxicity. It is particularly valued in obstetrics due to its rapid onset and safety profile for the neonate.
Peso molecular
270,7500 g/mol
LogP
2,90
TPSA
55,60 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl
InChI
InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
Molecular Formula
C13H19ClN2O2
HBD / HBA
1 / 4
Enlaces Rotables
7
Átomos Pesados
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A short-acting local anesthetic of the ester class that blocks sodium channels to reversibly inhibit nerve conduction, used primarily for epidural and spinal anesthesia in obstetric procedures. Its rapid hydrolysis by plasma cholinesterases results in a short duration of action and low systemic toxicity. It is particularly valued in obstetrics due to its rapid onset and safety profile for the neonate.
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Yes, Chloroprocaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1179047. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 8612. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="chloroprocaine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/chloroprocaine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/chloroprocaine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/chloroprocaine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="chloroprocaine"></drugfyi-drug>